Syntaxin 1A Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Syntaxin-1A Protein is a protein involved in neuronal signaling and function.
Gene: STX1A
UniProt: P61264
Molecular Weight: ~35 kDa
Subcellular Localization: Presynaptic plasma membrane, synaptic vesicles
Protein Family: Syntaxin family, SNARE proteins
Syntaxin-1A is a member of the SNARE (Soluble N-ethylmaleimide-sensitive factor Attachment Protein REceptor) protein family. It is a transmembrane protein with an N-terminal three-helix bundle (Habc domain), a SNARE motif (∼60 residues forming a coiled-coil), and a C-terminal transmembrane anchor. Syntaxin-1A forms a binary complex with SNAP-25 and a v-SNARE (synaptobrevin/VAMP) to form the SNARE complex that mediates synaptic vesicle fusion.
Syntaxin-1A is essential for neurotransmitter release at synapses. It interacts with multiple proteins including:
The protein is critical for synaptic vesicle docking, priming, and fusion. It also regulates calcium channel function at presynaptic terminals, linking calcium entry to vesicle release.
Syntaxin-1A expression and function are altered in AD brain. The protein is involved in amyloid precursor protein (APP) processing and Aβ secretion. Some studies suggest syntaxin-1A may be protective against Aβ toxicity. Changes in SNARE complex composition may contribute to synaptic dysfunction in AD.
tered syntaxin-Al1A has been reported in PD models. The protein interacts with α-synuclein and may be involved in Lewy body formation. Syntaxin-1A may also affect dopamine release through its interaction with VMAT2.
Syntaxin-1A and other SNARE proteins are affected in ALS. Changes in SNARE complex function may contribute to synaptic dysfunction and neuromuscular junction denervation.
Syntaxin-1A mutations have been linked to epilepsy in humans and animal models. The protein's role in regulating neurotransmitter release makes it a candidate for seizure susceptibility.
Syntaxin-1A is a challenging drug target due to its essential role in neurotransmitter release. However:
The study of Syntaxin 1A Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.